[HTML][HTML] Next steps toward eradication of hepatitis C in the era of direct acting antivirals

K Hesamizadeh, H Sharafi, MS Rezaee-Zavareh… - Hepatitis …, 2016 - ncbi.nlm.nih.gov
Results There are major steps that should be taken to eradicate HCV, including (1) the
development of screening strategies, particularly for groups such as intravenous drug users …

Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes

SM El Sayed, H Baghdadi, A Abou-Taleb… - Journal of blood …, 2014 - Taylor & Francis
Iron overload causes iron deposition and accumulation in the liver, heart, skin, and other
tissues resulting in serious tissue damages. Significant blood clearance from iron and ferritin …

Safety and efficacy of sofosbuvir and daclatasvir for hepatitis C virus infection in patients with β-thalassemia major

R Mehta, M Kabrawala, S Nandwani, P Desai… - Journal of clinical and …, 2018 - Elsevier
Background and Aims β-thalassemia major patients are susceptible to Hepatitis C Virus
(HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient …

Efficacy and safety of direct acting antiviral therapy for chronic hepatitis C in thalassemic children

S Padhi, S Maharshi, GK Gupta, K Garg… - Journal of pediatric …, 2018 - journals.lww.com
Objectives: There is limited data on the efficacy and safety of directly acting antiviral therapy
(DAA) for chronic hepatitis C in pediatric population. The aim was to assess the efficacy and …

[HTML][HTML] The role of polymorphisms near the IL28B gene on response to peg-interferon and ribavirin in thalassemic patients with hepatitis C

B Behnava, H Sharafi, M Keshvari, A Pouryasin… - Hepatitis …, 2016 - ncbi.nlm.nih.gov
Background Hepatitis C Virus (HCV) is the major cause of liver failure in thalassemic
patients. In these patients, iron overload and their comorbidities make difficulties during …

[HTML][HTML] Efficacy of prolonged treatment with pegylated interferon (Peg-IFN) and ribavirin in thalassemic patients with hepatitis C who relapsed after previous Peg-IFN …

S Sandoughdaran, SM Alavian, H Sharafi… - Hepatitis …, 2015 - ncbi.nlm.nih.gov
Background: Most thalassemic patients with chronic hepatitis C virus (HCV) infection do not
respond to therapy with pegylated interferon (Peg-IFN) plus ribavirin (RBV) due to hepatic …

The effectiveness of sofosbuvir and daclatasvir in the treatment of hepatitis C in thalassaemia major patients and their effect on haematological factors

F Zamani, H Ajdarkosh… - Indian journal of medical …, 2018 - Elsevier
Context: Patients with thalassaemia are at risk of infections such as hepatitis C virus (HCV)
due to their repeated blood transfusions; meanwhile, the treatment of thalassaemia patients …

Consensus statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL recommendations for management of HCV in …

P Puri, AC Anand, VA Saraswat, SK Acharya… - Journal of clinical and …, 2014 - Elsevier
The estimated prevalence of hepatitis C virus (HCV) infection in India is between 0.5 and
1.5% with hotspots showing much higher prevalence in some areas of northeast India, in …

The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience

NR Hussein, I Tunjel, Z Basharat, A Taha… - Epidemiology & …, 2016 - cambridge.org
Various variables that might influence the rapid and sustained virological response to
recombinant PEG-IFN-α-2a were explored in Iraqi HCV-infected patients with …

[HTML][HTML] The efficacy and safety of sofosbuvir-containing regimen in the treatment of HCV infection in patients with haemoglobinopathy

NR Hussein - Mediterranean journal of hematology and infectious …, 2017 - ncbi.nlm.nih.gov
Infection with HCV is a public health problem and is a leading cause of cirrhosis and liver
cancer. 1 HCV infection has been reported in 4.4% to 85.4% of subjects with thalassaemia …